Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an
in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients.
Secondary, the investigators will analyze progression rate of genetic-proving PARK8 and PARK6
patients who have homogeneous phenotype and genotype by 18F-DTBZ PET imaging.